47 results on '"Girod A"'
Search Results
2. A Cost Comparison of Treatment with Abiraterone Acetate Plus Prednisone in the Pre Chemotherapy Setting Followed By Enzalutamide in the Post-Chemotherapy Setting Versus the Opposite Treatment Sequence in Metastatic Castration Resistant Prostate Cancer Patients With non-Visceral Metastases
3. A Cost Comparison of Treatment with Abiraterone Acetate Plus Prednisone in the Pre Chemotherapy Setting Followed By Enzalutamide in the Post-Chemotherapy Setting Versus the Opposite Treatment Sequence in Metastatic Castration Resistant Prostate Cancer Patients With non-Visceral Metastases
4. Sources of Long-Term Quality Adjusted Life Year (QALY) Gains for Canagliflozin (CANA) Versus Sitagliptin (SITA) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
5. Sources of Long-Term Quality Adjusted Life Year (QALY) Gains for Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
6. PHP35 RESOURCE USE AND COSTS OF PATIENTS RECEIVING ENTERAL NUTRITION IN PRIMARY AND SECONDARY CARE IN THE UK
7. PGS7: ISSUES IN USING CONJOINT ANALYSIS TO VALUE HEALTH CARE WITHIN CLINICAL STUDIES
8. PCN137 - Modeling Treatments and Outcomes in Metastatic Castration-Resistant Prostate Cancer: A Case Study of Discrete Event Simulation and the Challenges for A UK Nice Evaluation
9. PUK16 EXPLORING THE IMPACT OF CHANGES IN NEUROGENIC URINARY INCONTINENCE FREQUENCY AND CONDITION SPECIFIC QUALITY OF LIFE ON PREFERENCE-BASED OUTCOMES
10. Impact of Patient Weight Trajectory on Cost-Effectiveness of Treatments of Type 2 Diabetes Mellitus (T2DM)
11. Assessment of the Key Drivers of Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
12. Sources of Long-Term Quality Adjusted Life Year (QALY) Gains for Canagliflozin (CANA) Versus Sitagliptin (SITA) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
13. Impact of Patient Weight Trajectory on Cost-Effectiveness of Treatments of Type 2 Diabetes Mellitus (T2DM)
14. Assessment of the Key Drivers of Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
15. PCN93 - A Cost Comparison of Treatment with Abiraterone Acetate Plus Prednisone in the Pre Chemotherapy Setting Followed By Enzalutamide in the Post-Chemotherapy Setting Versus the Opposite Treatment Sequence in Metastatic Castration Resistant Prostate Cancer Patients With non-Visceral Metastases
16. PUK16 EXPLORING THE IMPACT OF CHANGES IN NEUROGENIC URINARY INCONTINENCE FREQUENCY AND CONDITION SPECIFIC QUALITY OF LIFE ON PREFERENCE-BASED OUTCOMES
17. PGS4: PRESENTATION OF THE 23-ITEM WOMEN'S HEALTH QUESTIONNAIRE (WHQ): SCORING AND INTERPRETATION ISSUES
18. PKU3: LINGUISTIC VALIDATION OF THE URINARY INCONTINENCE QUALITY OF LIFE QUESTIONNAIRE
19. PWM5: COMPARISON OF QUALITY OF LIFE SCORES BETWEEN MENOPAUSAL WOMEN AND AGEMATCHED PEERS
20. TPQL1: DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF A QUALITY OF LIFE QUESTIONNAIRE IN URINARY INCONTINENCE (CONTILIFE®)
21. PND6 RETROSPECTIVE EVALUTION OF THE DOSES OF BOTOX AND DYSPORT IN THE MANAGEMENT OF DYSTONIA—A COST MINIMISATION ANALYSIS
22. PHP34 ENTERAL FEEDING IN THE COMMUNITY: A STUDY OF HEALTH ECONOMIC OUTCOMES USING THE GENERAL PRACTICE RESEARCH DATABASE (GPRD)
23. PHP35 RESOURCE USE AND COSTS OF PATIENTS RECEIVING ENTERAL NUTRITION IN PRIMARY AND SECONDARY CARE IN THE UK
24. PND6 RETROSPECTIVE EVALUTION OF THE DOSES OF BOTOX AND DYSPORT IN THE MANAGEMENT OF DYSTONIA—A COST MINIMISATION ANALYSIS
25. PHP30 THE IMPLICATIONS OF THE USE OF TUBE FEEDING IN THE UK SECONDARY HEALTH CARE SYSTEM
26. PGS7: ISSUES IN USING CONJOINT ANALYSIS TO VALUE HEALTH CARE WITHIN CLINICAL STUDIES
27. PGS6: METHODOLOGICAL ISSUES IN EVALUATING CONCEPTUAL EQUIVALENCE: APPLICATION TO THE WOMEN'S HEALTH QUESTIONNAIRE (WHQ)
28. PGS4: PRESENTATION OF THE 23-ITEM WOMEN'S HEALTH QUESTIONNAIRE (WHQ): SCORING AND INTERPRETATION ISSUES
29. PMT33: LINGUISTIC VALIDATION OF THE VASCULAR QUALITY OF LIFE QUESTIONNAIRE (VASCUQOL) IN 8 LANGUAGES
30. PHT8: DEVELOPMENT OF A NEW SCORING OF THE WOMEN'S HEALTH QUESTIONNAIRE (WHQ)
31. PWM3: IMPLICATIONS OF MENOPAUSAL SYMPTOMS ON QUALITY OF LIFE
32. PKU3: LINGUISTIC VALIDATION OF THE URINARY INCONTINENCE QUALITY OF LIFE QUESTIONNAIRE
33. PWM5: COMPARISON OF QUALITY OF LIFE SCORES BETWEEN MENOPAUSAL WOMEN AND AGEMATCHED PEERS
34. TPQL1: DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF A QUALITY OF LIFE QUESTIONNAIRE IN URINARY INCONTINENCE (CONTILIFE®)
35. PGS6: METHODOLOGICAL ISSUES IN EVALUATING CONCEPTUAL EQUIVALENCE: APPLICATION TO THE WOMEN'S HEALTH QUESTIONNAIRE (WHQ)
36. PDB60 - Sources of Long-Term Quality Adjusted Life Year (QALY) Gains for Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
37. PDB59 - Assessment of the Key Drivers of Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
38. PDB55 - Sources of Long-Term Quality Adjusted Life Year (QALY) Gains for Canagliflozin (CANA) Versus Sitagliptin (SITA) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
39. PDB53 - Impact of Patient Weight Trajectory on Cost-Effectiveness of Treatments of Type 2 Diabetes Mellitus (T2DM)
40. PWM3: IMPLICATIONS OF MENOPAUSAL SYMPTOMS ON QUALITY OF LIFE
41. PHP30 THE IMPLICATIONS OF THE USE OF TUBE FEEDING IN THE UK SECONDARY HEALTH CARE SYSTEM
42. PDB55 Sources of Long-Term Quality Adjusted Life Year (QALY) Gains for Canagliflozin (CANA) Versus Sitagliptin (SITA) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
43. PHT8: DEVELOPMENT OF A NEW SCORING OF THE WOMEN'S HEALTH QUESTIONNAIRE (WHQ)
44. PCN93 A Cost Comparison of Treatment with Abiraterone Acetate Plus Prednisone in the Pre Chemotherapy Setting Followed By Enzalutamide in the Post-Chemotherapy Setting Versus the Opposite Treatment Sequence in Metastatic Castration Resistant Prostate Cancer Patients With non-Visceral Metastases
45. PHP34 ENTERAL FEEDING IN THE COMMUNITY: A STUDY OF HEALTH ECONOMIC OUTCOMES USING THE GENERAL PRACTICE RESEARCH DATABASE (GPRD)
46. PDB59 Assessment of the Key Drivers of Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
47. PDB53 Impact of Patient Weight Trajectory on Cost-Effectiveness of Treatments of Type 2 Diabetes Mellitus (T2DM)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.